Response of rosacea to isotretinoin

Marsden, J.R.; Shuster, Sam; Neugebauer, Maria Gertrudes Fernandes Pereira

doi:10.1111/j.1365-2230.1984.tb00842.x

Cited by 39 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Forty-two studies were included in this quality assessment evaluating the treatment of rosacea [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]. The study design of these papers included 29 double-blind, 1 single-blind, and 9 open-labeled reports.…”

Section: Resultsmentioning

confidence: 99%

Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician

Gupta

Chaudhry

2003

Dermatology

View full text Add to dashboard Cite

Background: Patients suffering from rosacea may experience frequent blushing and flushing, erythema, telangiectasia, and/or rhinophyma. In an attempt to find effective treatments, many studies have been performed. Objective: It is important to be able to evaluate the quality of clinical trials where agents have been used to treat rosacea, and to compare the effectiveness of the different therapies used for this indication. Methods: The reports on the efficacy and safety of the different drug therapies were evaluated using predetermined criteria. We searched MEDLINE (1966–2002) for studies where rosacea was treated with the various therapies. The criteria used to assess the quality of the studies were: randomization, blinding (double, single, or open), aims clearly defined, prior sample size calculation, whether inclusion and/or exclusion criteria were outlined, baseline comparison of patient characteristics and demographics, interventions and efficacy parameters defined, compliance assessed, statistical analysis performed including intention-to-treat evaluation of efficacy of therapy. Results: Using the above-mentioned criteria, each study was rated in order to determine the quality of the clinical trial. The maximum score a study could attain was 20. To determine if high-quality studies are cited more often than the lower-quality papers, the number of times a study had been cited since its publication was measured. We found 13 of the 42 studies scored greater than 14; these studies were rated as high-quality studies. There was no significant association between high-quality papers and the number of times they had been cited, suggesting that other factors are also taken into consideration when a given study is cited. Conclusion: It is important for investigators and clinicians to be aware of the parameters that count towards designing a high-quality protocol since such studies are more likely to reflect efficacy rates that are accurate. Furthermore, it is essential that when a study is written up, the pertinent information regarding the design of the trial and the manner in which it was conducted are conveyed to the reader.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician

Gupta

Chaudhry

2003

Dermatology

View full text Add to dashboard Cite

show abstract

“…Minimal erythema has been persistent in responsive patients until late into therapy. 70,73 Although interpretation is limited by their small sample size, Irvine, Kumar, and Marks observed, using a laser-Doppler device (Perimed), that cutaneous blood flow on the cheek, when measured at 258C and 348C, was not reduced in patients who underwent oxytetracycline treatment. In contrast, patients in the isotretinoin group showed significantly reduced facial cutaneous blood flow by means of laserDoppler at both temperatures at 10 weeks.…”

Section: Isotretinoinmentioning

confidence: 97%

“…[69][70][71][72][73] The effects of isotretinoin can be delayed in comparison with standard therapies, 46,74 although a reduction of papule counts may be evident as early as 2 weeks. 70 Irvine, Kumar, and Marks treated erythematotelangiectatic and papulopustular rosacea with either oxytetracycline (n = 6; 250 mg twice daily) or isotretinoin (n = 5; 30 mg daily) for a 2-month period.…”

Section: Isotretinoinmentioning

confidence: 99%

Rosacea: II. Therapy

Pelle

Crawford

James

2004

Journal of the American Academy of Dermatology

179

168

View full text Add to dashboard Cite

“…B. der Kaliumjodidepikutantest, ergaben eine deutliche dosisabhängige Reduktion des Erythems und Ödems sowie der Papeln und Pusteln, wobei damals für die Aknetherapie übliche Dosierungen zwischen 0,5 und 1,0 mg/kg KG angewandt wurden [18]. Auch von anderen Arbeitsgruppen konnte bei dieser Dosierung eine sehr gute Reduktion der Seborrhö, der entzündlichen Effloreszenzen und des Erythems während einer Therapiedauer von 8-12 Wochen bestätigt werden [14,25]. Milde dosisabhängige Anstiege der Triglyzeride, des Cholesterols und der Transaminasen wurden beobachtet, erforderten jedoch keinen Therapieabbruch.…”

Section: Historischesunclassified

“…In einer ersten Studienphase wurden die Patienten in einer Dosierung von 0,1 mg/kg KG, 0,3 mg/kg KG und 0,5 mg/kg KG täglich behandelt. Als Vergleichsgruppen dienten Placebo und Doxycyclin in einer Dosierung von 100 mg/Tag über 14 Sowohl in der Beurteilung der Untersucher als auch der Patienten zeigte sich eine leichte Überlegenheit von Isotretinoin: Eine komplette Remission wurde bei 24% der Isotretinoin-behandelten Patienten und bei 13,6% der Doxycyclin-behandelten Patienten festgestellt, während 32,6% (Isotretinoin 0,3 mg/kg) vs. 24,2% (Doxycyclin) der Patienten den Therapieerfolg als "exzellent" bewerteten.…”

Section: Dosierung Und Nebenwirkungsspektrum Von Isotretinoin Bei Rosunclassified

Rosazea

Thielitz

Gollnick

2011

Hautarzt

View full text Add to dashboard Cite

Systemic isotretinoin has been known for decades as an effective and safe therapeutic option in the treatment of severe and refractory forms of rosacea. It can also be used in special treatment-resistant forms of rosacea, e.g. granulomatous rosacea, as efficacious second-line therapy. Previously, the effect of isotretinoin in rosacea has been mainly studied in small cohorts or anecdotal reports. Recently, a big randomized double-blind dose-response and comparative study revealed that an optimized dosage of 0,3 mg/kg was superior to other dosages and non-inferior to doxycycline as gold standard of systemic rosacea treatment and proved effective and safe in papulopustular and phymatous subtypes. However, the substance is still not licensed for this indication The efficacy of isotretinoin in rosacea is probably mainly related to anti-inflammatory mechanisms as well as anti-oxidative, anti-angiogenic and antifibrotic properties. The classical antiseborrheic effect of isotretinoin might play a role in special subtypes like the phymatous type or rosacea fulminans.

show abstract

Response of rosacea to isotretinoin

Cited by 39 publications

References 4 publications

Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician

Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician

Rosacea: II. Therapy

Rosazea

Contact Info

Product

Resources

About